Novel approaches to regulate GvHD should focus on the preservation of PD-L1 expression on host hematopoietic and non-hematopoietic host cells of GvHD target organs alone or in combination with adoptive therapy using ex vivo expanded Tregs in the graft, with the goal of providing potential therapeutic benefit against GvHD. This evidence concerns the gene CD274 and graft versus host disease.